vs
Side-by-side financial comparison of Karyopharm Therapeutics Inc. (KPTI) and PCB BANCORP (PCB). Click either name above to swap in a different company.
Karyopharm Therapeutics Inc. is the larger business by last-quarter revenue ($34.1M vs $29.2M, roughly 1.2× PCB BANCORP). On growth, Karyopharm Therapeutics Inc. posted the faster year-over-year revenue change (11.6% vs 11.3%). Over the past eight quarters, PCB BANCORP's revenue compounded faster (10.4% CAGR vs 1.4%).
PCB Bank is an American community bank that focuses on the Korean-American community based in California and offers commercial banking services. It has branches in 8 states and is the third largest Korean American Bank after Bank of Hope and Hanmi Bank.
KPTI vs PCB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.1M | $29.2M |
| Net Profit | $-102.2M | — |
| Gross Margin | — | — |
| Operating Margin | -52.4% | 45.0% |
| Net Margin | -299.9% | — |
| Revenue YoY | 11.6% | 11.3% |
| Net Profit YoY | -232.0% | — |
| EPS (diluted) | $-7.02 | $0.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.1M | $29.2M | ||
| Q3 25 | $44.0M | $30.4M | ||
| Q2 25 | $37.9M | $29.3M | ||
| Q1 25 | $30.0M | $26.9M | ||
| Q4 24 | $30.5M | $26.2M | ||
| Q3 24 | $38.8M | $25.3M | ||
| Q2 24 | $42.8M | $24.2M | ||
| Q1 24 | $33.1M | $23.9M |
| Q4 25 | $-102.2M | — | ||
| Q3 25 | $-33.1M | $11.4M | ||
| Q2 25 | $-37.3M | $9.1M | ||
| Q1 25 | $-23.5M | $7.7M | ||
| Q4 24 | $-30.8M | — | ||
| Q3 24 | $-32.1M | $7.8M | ||
| Q2 24 | $23.8M | $6.3M | ||
| Q1 24 | $-37.4M | $4.7M |
| Q4 25 | -52.4% | 45.0% | ||
| Q3 25 | -34.6% | 52.3% | ||
| Q2 25 | -64.3% | 43.3% | ||
| Q1 25 | -110.8% | 40.2% | ||
| Q4 24 | -102.4% | 39.3% | ||
| Q3 24 | -67.8% | 42.2% | ||
| Q2 24 | -65.7% | 36.3% | ||
| Q1 24 | -101.9% | 27.2% |
| Q4 25 | -299.9% | — | ||
| Q3 25 | -75.2% | 37.5% | ||
| Q2 25 | -98.2% | 31.0% | ||
| Q1 25 | -78.2% | 28.8% | ||
| Q4 24 | -100.8% | — | ||
| Q3 24 | -82.7% | 30.8% | ||
| Q2 24 | 55.6% | 25.9% | ||
| Q1 24 | -112.8% | 19.6% |
| Q4 25 | $-7.02 | $0.65 | ||
| Q3 25 | $-3.82 | $0.78 | ||
| Q2 25 | $-4.32 | $0.62 | ||
| Q1 25 | $-2.77 | $0.53 | ||
| Q4 24 | $-2.33 | $0.46 | ||
| Q3 24 | $-3.85 | $0.52 | ||
| Q2 24 | $-2.97 | $0.43 | ||
| Q1 24 | $-4.85 | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $60.5M | $207.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-292.9M | $390.0M |
| Total Assets | $108.4M | $3.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.5M | $207.1M | ||
| Q3 25 | $37.7M | $369.5M | ||
| Q2 25 | $38.7M | $263.6M | ||
| Q1 25 | $38.8M | $214.3M | ||
| Q4 24 | $62.5M | $198.8M | ||
| Q3 24 | $72.8M | $193.1M | ||
| Q2 24 | $84.8M | $177.6M | ||
| Q1 24 | $30.6M | $239.8M |
| Q4 25 | $-292.9M | $390.0M | ||
| Q3 25 | $-269.3M | $384.5M | ||
| Q2 25 | $-238.9M | $376.5M | ||
| Q1 25 | $-205.9M | $370.9M | ||
| Q4 24 | $-186.0M | $363.8M | ||
| Q3 24 | $-159.6M | $362.3M | ||
| Q2 24 | $-132.1M | $353.5M | ||
| Q1 24 | $-169.0M | $350.0M |
| Q4 25 | $108.4M | $3.3B | ||
| Q3 25 | $96.2M | $3.4B | ||
| Q2 25 | $104.9M | $3.3B | ||
| Q1 25 | $127.7M | $3.2B | ||
| Q4 24 | $164.4M | $3.1B | ||
| Q3 24 | $189.5M | $2.9B | ||
| Q2 24 | $214.0M | $2.9B | ||
| Q1 24 | $204.5M | $2.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.8M | $26.6M |
| Free Cash FlowOCF − Capex | — | $24.4M |
| FCF MarginFCF / Revenue | — | 83.6% |
| Capex IntensityCapex / Revenue | 0.0% | 7.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $46.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.8M | $26.6M | ||
| Q3 25 | $-5.9M | $16.4M | ||
| Q2 25 | $-18.7M | $4.9M | ||
| Q1 25 | $-39.0M | $2.3M | ||
| Q4 24 | $-25.8M | $39.0M | ||
| Q3 24 | $-19.5M | $11.9M | ||
| Q2 24 | $-38.5M | $14.6M | ||
| Q1 24 | $-43.7M | $8.2M |
| Q4 25 | — | $24.4M | ||
| Q3 25 | — | $16.2M | ||
| Q2 25 | — | $3.8M | ||
| Q1 25 | — | $1.6M | ||
| Q4 24 | $-25.9M | $34.9M | ||
| Q3 24 | — | $11.9M | ||
| Q2 24 | — | $12.8M | ||
| Q1 24 | $-43.9M | $6.0M |
| Q4 25 | — | 83.6% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 13.1% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | -84.7% | 133.2% | ||
| Q3 24 | — | 46.8% | ||
| Q2 24 | — | 53.1% | ||
| Q1 24 | -132.6% | 25.2% |
| Q4 25 | 0.0% | 7.5% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.0% | 3.7% | ||
| Q1 25 | 0.0% | 2.8% | ||
| Q4 24 | 0.2% | 15.5% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | 0.0% | 7.3% | ||
| Q1 24 | 0.6% | 9.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.52× | ||
| Q2 24 | -1.62× | 2.33× | ||
| Q1 24 | — | 1.76× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
PCB
Segment breakdown not available.
